HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California Stretches Prop 65 Short-Form Warning Label Size But Sticks To Language Standard

Executive Summary

Changes to proposed rule include increasing from 5 to 12 square inches the space allowed for a short-form warning, but use remains restricted to packages with limited available space for information that wouldn’t easily accommodate full warning. State’s accepting comments through 14 January.

You may also be interested in...



Beauty Firms Hit With Prop 65 Notice: Don’t Ignore Or Retailers May ‘Blackball’ You

Ballard Spahr attorney Brendan Collins warned attendees to take Prop 65 violation notices seriously and address them in a timely manner, speaking at the Independent Beauty Association’s 2022 Technical Regulatory Forum.

Like COVID-19 Impact On Supply Chain, Expert Says Global Demand For Goods ‘Unprecedented’

UCLA professor Chris Tang says like most US businesses relying on supplies or production from outside the country, particularly from China, consumer health and beauty and personal care product companies should expect at least another year of supply disruption.

California’s Prop 65 Short-Form Warning Changes Are Costly, Confusing And Quick – Lawyer

California’s proposal to amend ‘Clear and Reasonable’ safe harbor warnings will be costly for companies and confusing to consumers, and the one-year phase-in for changes to Prop 65 warnings is “unrealistic,” says consumer product and environmental regulation lawyer Dennis Raglin.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel